E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Marine-derived Bioactive Peptides and Lipids Applied in Non-communicable Diseases"

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: 30 September 2018

Special Issue Editor

Guest Editor
Dr. Constantina Nasopoulou

Department of Food Science and Nutrition, School of the Environment, University of the Aegean, Metropolite Ioakeim 2, 81400 Myrina, Lemnos, Greece
Website | E-Mail
Interests: functional food products of animal origin; food biotechnology; food safety and quality; atherosclerosis

Special Issue Information

Dear Colleagues,

Non-communicable diseases, such as cardiovascular diseases, different types of cancer, respiratory diseases and diabetes, are the leading cause of death globally. Marine species are valuable source of bioactive constituents, such as peptides, proteins and lipids. Marine-derived biopeptides—due to their structural properties and their amino acids composition and sequences - exhibit various biological activities such as anti-atherosclerotic, anti-hypertensive, anti-cancer, anti-diabetic, anti-oxidative, anti-obesity activity, etc., preventing non-communicable diseases. Additionally, marine-derived bioactive lipids such as marine phosholipids have high content of the long-chain polyunsaturated omega-3 fatty acids EPA and DHA and exhibit numerous biological properties against atherosclerosis, thrombosis and inflammation. Therefore, the purpose of the current Special Issue is to publish novel ideas related to the therapeutic potential of marine-derived bioactive peptides and lipids in the treatment or prevention of non-communicable diseases, underlining the possible use of the aforementioned bioactive constituents as functional food ingredients, nutraceuticals or pharmaceuticals.

Dr. Constantina Nasopoulou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Marine species
  • Marine-derived bioactive peptides
  • Marine-derived bioactive phospholipids
  • Non-communicable diseases
  • Nutraceuticals

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:


Open AccessArticle Structural Elucidation of Irish Organic Farmed Salmon (Salmo salar) Polar Lipids with Antithrombotic Activities
Mar. Drugs 2018, 16(6), 176; https://doi.org/10.3390/md16060176
Received: 17 April 2018 / Revised: 16 May 2018 / Accepted: 22 May 2018 / Published: 23 May 2018
Cited by 1 | PDF Full-text (3602 KB) | HTML Full-text | XML Full-text
While several marine polar lipids (PL) have exhibited cardioprotective properties through their effects on the platelet-activating factor (PAF) pathways, salmon PL have not been tested so far. In this study, the antithrombotic activities of salmon PL were assessed in human platelets and the
[...] Read more.
While several marine polar lipids (PL) have exhibited cardioprotective properties through their effects on the platelet-activating factor (PAF) pathways, salmon PL have not been tested so far. In this study, the antithrombotic activities of salmon PL were assessed in human platelets and the structural characterisation of bioactive salmon PL was performed by GC-MS and LC-MS analyses. PL from fillets of Irish organic farmed salmon (Salmo salar) were extracted and separated into several lipid subclasses by thin-layer chromatography (TLC), while their fatty acid profile was fully characterised by GC-MS. Salmon total lipids (TL), total neutral lipids (TNL), total polar lipids (TPL), and each PL subclass obtained by TLC were further assessed for their in vitro effects towards PAF-induced and thrombin-induced platelet aggregation in human platelets. Salmon PL exhibited antithrombotic effects on human platelet aggregation, mostly through their strong inhibitory effects against the PAF pathway with IC50 values comparable to other marine PL, but with lower effects towards the thrombin pathway. PL fractions corresponding to phosphatidylcholine and phosphatidylethanolamine derivatives exhibited the most potent anti-PAF effects, while LC-MS analysis putatively elucidated their structure/function relationship. Several diacyl-PC/PE and alkyl-acyl-PC/PE species containing mostly docosahexaenoic acid at their sn-2 glycerol-backbone may be responsible for the bioactivity. The data presented suggests that salmon contains PL with strong antithrombotic bioactivities. Full article

Graphical abstract

Back to Top